Table 5

Immunohistochemical markers in the differential diagnosis of endometrial carcinomas versus endocervical adenocarcinomas

Endometrial carcinoma
EMC+++wt>M−/+PTEN and MMR loss
CCC+wt>M+−/+HNF1β, Napsin A
MMR loss
UCM>wt−/+E-cadherin and MMR loss
MMMT+−/+−/+M++/−Myogenin, S100, Myo-D1. Biphasic pattern
Endocervical adenocarcinoma
EAC, usual type−/+−/+wt+−/++HPV+
MC, gastric typeM>wt−/+++/−MUC6, HIK1083, STK11 mutation
MC, intestinal type++CDX2, HPV+
Mesonephric carcinoma+/−−/+wt−/+−/+TTF1, GATA3, calretinin
Serous carcinoma−/+−/+wt>M+NA−/++HPV+
Clear cell carcinoma−/+wt>M+/−+−/+Napsin A, PIK3CA mutation
  • p53 M corresponds to intense and diffuse positivity in ≥60% of cells or complete negativity; p53 wt is the presence of rare cells weakly positive or positivity in <60% of cells.

  • AIS, endocervical adenocarcinoma in situ, of usual type; CCC, clear cell carcinoma; EAC, endocervical adenocarcinoma; EMC, endometrioid carcinoma; HPV+, human papilloma virus infection in situ hybridisation; M, mutant pattern; MMMT, malignant mixed Müllerian tumour; MMR, DNA mismatch repair genes; UC, undifferentiated carcinoma; USC, uterine serous carcinoma; wt, wild-type pattern.